PA-SES
24.9.2020 08:52:58 CEST | Business Wire | Press release
SES Government Solutions (SES GS), a fully-owned affiliate of SES, and Isotropic Systems, a leading developer of transformational broadband terminal technologies, today announced a two-phased antenna evaluation contract with the U.S. Air Force Research Laboratory, working in close collaboration with the U.S. Army Research Engineering Team, for tests of Isotropic Systems’ multi-beam terminal over SES’s O3b Medium Earth Orbit (MEO) constellation to ultimately unleash next-gen connectivity across the battlefield.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200923006010/en/
It is the first customer contract between Isotropic Systems and SES Government Solutions and follows on from the significant developmental partnership currently ongoing between the two companies to produce scalable, cost-effective terminals capable of providing government, military, and commercial access to the existing O3b constellation and the groundbreaking O3b mPOWER system set to launch late next year.
The U.S. Air Force and Army, through the innovative Defense Experimentation Using Commercial Space Internet (DEUCSI) program, will review a prototype of Isotropic Systems’ optical beamforming antenna and its ability to connect simultaneously with two satellite constellations at GEO and MEO. The unique multi-beam capability will enable the armed forces to deliver data at the tactical edge by leveraging capacity from multiple commercial satellites and a military satellite over a single antenna platform.
First phase over-the-air (OTA) is scheduled to be completed by early fall, followed by the phase two in early 2021 where the Isotropic Systems optical lens technology will be utilized to demonstrate a two full performance beam connection. One beam will link with an SES geostationary (GEO) satellite, while another full performance optical beam will establish a simultaneous connection with SES’s O3b MEO satellite constellation.
The biggest user of satellite capacity in the world, the U.S. Department of Defense, is exploring new ways to more effectively and efficiently utilize both existing and new capacity coming online in GEO, MEO and LEO orbits. Isotropic Systems’ optical multi-beam terminals bring key advantages to government markets, including the flexibility to meet performance, cost, and power consumption requirements specific to defense.
"As we get ready for the launch of our O3b mPOWER MEO constellation and SES-17 GEO satellite late next year, it is vital that we work with the U.S. Government to better understand their requirements, and to partner with companies like Isotropic Systems to help us meet those needs," said Pete Hoene, President and CEO of SES Government Solutions. "The Isotropic antenna will deliver high throughput, at low latency over a MEO constellation with simultaneous resilient GEO capacity. This will be a game-changer for the U.S. Army. These collaborative trials with the U.S. Army Research Engineering Team and the Air Force bring commercial ingenuity to the men and women in uniform and the U.S. Government as a whole."
“Isotropic Systems’ collaborative tests with SES Government Solutions in support of the U.S. military is an important milestone on our roadmap leading to a multi-beam, multi-frequency terminal that allows the government and armed forces to utilize every bit of capacity in the sky,” said Scott Sprague, Chief Commercial Officer of Isotropic Systems. “That is the ultimate goal for the defense market, which is currently grappling with disparate networks to deliver connectivity to the battlespace.”
Follow us on:
Social Media
Blog
Media Library
About SES Government Solutions
SES Government Solutions (SES GS) is a wholly-owned subsidiary of global satellite operator SES. SES GS operates under a proxy board allowing them to provide services through contracts with the U.S. Government, including classified work. SES GS is exclusively focused on meeting the satellite communications needs of the U.S. Government. Leveraging more than four decades of experience in the government SATCOM market, SES Government Solutions offers robust and secure end-to-end satellite communications solutions. Further information can be found at www.ses-gs.com
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,300 channels and has an unparalleled reach of 367 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com .
About Isotropic Systems
Isotropic Systems is developing the world’s first multi-service, high-bandwidth, low power, fully integrated high throughput terminals designed to support the satellite industry to 'reach beyond' traditional markets and acquire new customers with a full suite of high throughput services. The company’s team of industry experts and scientists has pioneered several firsts in satellite terminal design resulting in a line of terminals that are customizable to meet the performance, cost and power requirements of countless applications – from the most complex government defense systems and mobile backhaul solutions capable of extending 5G, to next-gen connected experiences aboard commercial airliners, cruise ships, offshore rigs, and even small fishing boats at sea. Isotropic Systems’ Series A funding was led by Boeing to advance space-based connectivity. Further information is available at www.isotropicsystems.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200923006010/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom